Jessica Fye
Stock Analyst at JP Morgan
(4.17)
# 448
Out of 4,935 analysts
195
Total ratings
59.84%
Success rate
10.16%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| HALO Halozyme Therapeutics | Maintains: Neutral | $60 → $63 | $62.90 | +0.16% | 14 | Aug 7, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $348 → $475 | $438.93 | +8.22% | 8 | Aug 6, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $245 → $254 | $191.49 | +32.64% | 13 | Jul 29, 2025 | |
| ONC BeOne Medicines | Maintains: Overweight | $321 → $345 | $287.36 | +20.06% | 3 | Jul 17, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $515 → $517 | $366.54 | +41.05% | 9 | Jul 14, 2025 | |
| INCY Incyte | Maintains: Neutral | $68 → $67 | $78.39 | -14.53% | 7 | Jul 14, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $108 → $113 | $57.33 | +97.10% | 4 | Jul 14, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $350 → $330 | $301.50 | +9.45% | 17 | Jul 8, 2025 | |
| INSM Insmed | Maintains: Overweight | $90 → $111 | $109.55 | +1.32% | 8 | Jul 8, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $45 → $48 | $41.64 | +15.27% | 5 | Jun 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underweight | $33 → $26 | $26.12 | -0.46% | 13 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $120 → $116 | $111.66 | +3.89% | 12 | May 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 → $13 | $8.31 | +56.44% | 6 | May 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $32.01 | +56.23% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $28 | $11.13 | +151.57% | 4 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $209 | $111.30 | +87.78% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $24 | $13.96 | +71.92% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $26 | $26.71 | -2.66% | 6 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $12.16 | +146.71% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $54 | $26.85 | +101.12% | 5 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $39 | $59.97 | -34.97% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $13.10 | -0.76% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $23.06 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $8.57 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $1.87 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $14.92 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $76 | $37.00 | +105.41% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.70 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.53 | +1,337.91% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $1.08 | +548.15% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $6.30 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $8.37 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $6.92 | - | 1 | Feb 8, 2018 |
Halozyme Therapeutics
Aug 7, 2025
Maintains: Neutral
Price Target: $60 → $63
Current: $62.90
Upside: +0.16%
Alnylam Pharmaceuticals
Aug 6, 2025
Maintains: Overweight
Price Target: $348 → $475
Current: $438.93
Upside: +8.22%
Ascendis Pharma
Jul 29, 2025
Maintains: Overweight
Price Target: $245 → $254
Current: $191.49
Upside: +32.64%
BeOne Medicines
Jul 17, 2025
Maintains: Overweight
Price Target: $321 → $345
Current: $287.36
Upside: +20.06%
Vertex Pharmaceuticals
Jul 14, 2025
Maintains: Overweight
Price Target: $515 → $517
Current: $366.54
Upside: +41.05%
Incyte
Jul 14, 2025
Maintains: Neutral
Price Target: $68 → $67
Current: $78.39
Upside: -14.53%
BioMarin Pharmaceutical
Jul 14, 2025
Maintains: Overweight
Price Target: $108 → $113
Current: $57.33
Upside: +97.10%
United Therapeutics
Jul 8, 2025
Maintains: Overweight
Price Target: $350 → $330
Current: $301.50
Upside: +9.45%
Insmed
Jul 8, 2025
Maintains: Overweight
Price Target: $90 → $111
Current: $109.55
Upside: +1.32%
Ionis Pharmaceuticals
Jun 12, 2025
Maintains: Neutral
Price Target: $45 → $48
Current: $41.64
Upside: +15.27%
May 22, 2025
Maintains: Underweight
Price Target: $33 → $26
Current: $26.12
Upside: -0.46%
May 22, 2025
Maintains: Neutral
Price Target: $120 → $116
Current: $111.66
Upside: +3.89%
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $8.31
Upside: +56.44%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $32.01
Upside: +56.23%
Apr 10, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $11.13
Upside: +151.57%
Feb 26, 2025
Maintains: Overweight
Price Target: $200 → $209
Current: $111.30
Upside: +87.78%
Jan 7, 2025
Maintains: Overweight
Price Target: $28 → $24
Current: $13.96
Upside: +71.92%
Oct 25, 2024
Maintains: Neutral
Price Target: $32 → $26
Current: $26.71
Upside: -2.66%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $12.16
Upside: +146.71%
Jul 9, 2024
Maintains: Overweight
Price Target: $47 → $54
Current: $26.85
Upside: +101.12%
Jun 18, 2024
Maintains: Overweight
Price Target: $31 → $39
Current: $59.97
Upside: -34.97%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $13.10
Upside: -0.76%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $23.06
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $8.57
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $1.87
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $14.92
Upside: -
Apr 19, 2023
Maintains: Overweight
Price Target: $65 → $76
Current: $37.00
Upside: +105.41%
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.70
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $1.53
Upside: +1,337.91%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $1.08
Upside: +548.15%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $6.30
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $8.37
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $6.92
Upside: -